Eagle Pharma Announces Changes To Its Board Of Directors; Director, Michael Graves Appointed Chairman

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or the “Company”) today announced that Douglas L. Braunstein, co-founder of Hudson Executive Capital LP and former Vice Chairman and Chief Financial Officer, JPMorgan Chase & Co., and Robert Glenning, President Financial Services Division and Chief Financial Officer, Hackensack Meridian Health have joined Eagle’s Board of Directors. Director, Michael Graves, has been appointed Chairman of the Board of Directors and Chairman of the Compensation Committee, replacing Jay Moorin in each of those roles. Directors, Jay Moorin and Dr. Alain Schreiber have resigned their board seats. Mr. Braunstein’s investment firm, Hudson Executive Capital LP, holds a 6.1% equity interest in Eagle’s common stock.